Relx (NYSE:RELX) Lowered to Hold Rating by StockNews.com

Relx (NYSE:RELX) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

Separately, Redburn Atlantic initiated coverage on shares of Relx in a research note on Wednesday, January 8th. They set a “buy” rating on the stock.

Relx Stock Up 0.3 %

Shares of NYSE:RELX opened at $48.50 on Tuesday. The company has a debt-to-equity ratio of 1.46, a current ratio of 0.52 and a quick ratio of 0.47. The firm has a market capitalization of $90.14 billion, a PE ratio of 26.08, a price-to-earnings-growth ratio of 2.73 and a beta of 0.90. The firm’s 50-day moving average is $48.42 and its two-hundred day moving average is $47.49. Relx has a 1 year low of $40.25 and a 1 year high of $51.99.

Hedge Funds Weigh In On Relx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. CENTRAL TRUST Co raised its stake in shares of Relx by 1,290.2% during the fourth quarter. CENTRAL TRUST Co now owns 570 shares of the technology company’s stock worth $26,000 after purchasing an additional 529 shares during the last quarter. Versant Capital Management Inc purchased a new stake in shares of Relx during the fourth quarter worth approximately $31,000. Transce3nd LLC purchased a new stake in shares of Relx during the fourth quarter worth approximately $40,000. Sierra Ocean LLC purchased a new stake in shares of Relx during the fourth quarter worth approximately $43,000. Finally, Brown Brothers Harriman & Co. raised its stake in shares of Relx by 218.5% during the fourth quarter. Brown Brothers Harriman & Co. now owns 965 shares of the technology company’s stock worth $44,000 after purchasing an additional 662 shares during the last quarter. 15.02% of the stock is owned by institutional investors and hedge funds.

About Relx

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.